Patent intelligence · US
US 9763974
Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
Patent details — US 9763974
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 19, 2017
- Expiration
- Sep 14, 2037
- Applicant
- GALECTIN THERAPEUTICS, INC.
- Claims
- 14
- CPC classes
- A61K, A61K31/715, A61K31/736, A61K31/738
Quick answer
US 9763974 (Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase) is held by GALECTIN THERAPEUTICS, INC.. Status: granted. Granted Sep 19, 2017. Expires Sep 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GALECTIN THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/715, A61K31/736, A61K31/738, A61K45/06, A61P
More from GALECTIN THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12377102
Compounds for the prevention and treatment of medical disorders and uses thereof
granted -
US 11583530
Compounds for the prevention and treatment of medical disorders and uses thereof
granted -
US 11576924
Compounds for the prevention and treatment of diseases and the use thereof
granted -
US 11413303
Methods for treatment of arthritis
granted -
US 10799525
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 10744154
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
granted -
US 10420793
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 9974802
Composition of novel carbohydrate drug for treatment of human diseases
granted
Frequently asked questions
What is US patent 9763974?
US 9763974 (Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase) is held by GALECTIN THERAPEUTICS, INC.. Status: granted. Granted Sep 19, 2017. Expires Sep 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9763974?
GALECTIN THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 9763974 expire?
Our index shows an expiration date of Sep 14, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.